Company news

Genprex, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants

December 23, 2020

Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants

December 21, 2020

Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

December 21, 2020

Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy

December 7, 2020

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

November 29, 2020

Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD

November 9, 2020

Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer

October 29, 2020

Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

October 28, 2020

Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing

October 25, 2020

Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing

September 20, 2020

Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs

September 1, 2020

Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate

June 24, 2020

Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™ Clinical Development

June 15, 2020

Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises

May 27, 2020

Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies

May 4, 2020

Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations

April 20, 2020

Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders

March 23, 2020

Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives

March 22, 2020

Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants

February 20, 2020

Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants

February 18, 2020

Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

February 10, 2020

Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering

January 27, 2020

Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market

January 22, 2020

Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer

January 20, 2020

Genprex Announces $1.26 Million Registered Direct Offering

November 19, 2019

Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers

November 18, 2019

← Newer news releases

Decks

The 5 newest of 26 decks. Every deck is listed under its year.